SYNB1934
Phase 2Small molecule
SYNB1934 is one of 16 small molecule programs targeting Phenylketonuria. It is currently in Phase 2.
1
Indications
2
Total Trials
0
Active Trials
15
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
29 competitors in Phenylketonuria
#DrugCompanyPhaseTrials
1Avelox
BayerApproved
L-Carnitine
IIperboreal Pharma Srl
Approved
BMN 333
BioMarin PharmaceuticalPhase 2
CEB-01
BioMarin PharmaceuticalPhase 3
PTC923
PPTC Therapeutics
Phase 3
Kuvan
BioMarin PharmaceuticalPreclinical
Immunosuppression
NNational Heart, Lung, and Blood Institute (NHLBI)
Phase 2
Kuvan
BioMarin PharmaceuticalPreclinical
Tetrahydrobiopterin
OOrphanetics Pharma Entwicklungs GmbH
Phase 1
Kuvan
BioMarin PharmaceuticalPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SYNB1934. EMBL-EBI & Wellcome Sanger Institute.
- [4]